#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should understand that older adult patients increasingly prefer CBD-dominant or balanced CBD/THC products over THC-alone formulations, which has direct implications for dosing recommendations and product selection in geriatric populations. This preference pattern suggests clinicians need to discuss specific cannabinoid ratios with older patients rather than assuming uniform cannabis products, as individual tolerability and efficacy preferences vary significantly by age group. Public safety workers’ legal access to medical cannabis off-duty may reduce stigma around cannabis use for work-related conditions like PTSD and chronic pain, potentially increasing patient disclosures about cannabis use during clinical assessments.
A recent analysis of cannabis product preferences among older adults demonstrates a significant shift toward cannabidiol (CBD)-dominant or balanced CBD:THC formulations, with substantially fewer seniors selecting THC-only products. This preference pattern has important implications for clinicians prescribing cannabis to geriatric patients, as it suggests this population may be seeking therapeutic benefits while minimizing psychoactive effects and associated risks such as cognitive impairment, falls, and drug interactions. The finding aligns with known age-related pharmacokinetic changes that increase older adults’ sensitivity to THC and the higher prevalence of comorbidities in this group that contraindicate high-THC exposure. For clinicians managing pain, anxiety, or other conditions in older patients with cannabis, these data support a patient-centered approach that prioritizes CBD-rich or balanced formulations as initial options, with careful titration and monitoring if THC is introduced. Clinicians should counsel older patients that CBD-dominant products may offer a better safety profile while reserving higher-THC options for carefully selected cases with robust monitoring and consideration of alternative therapies.
“What we’re seeing in the data mirrors what I observe in my clinic: older patients have more nuanced cannabinoid preferences based on their specific symptoms and side effect tolerance, and they’re often more cautious about THC-dominant products because they’re managing multiple medications and concerned about cognitive effects. This preference shift is clinically important because it tells us that one-size-fits-all dosing recommendations don’t serve our aging population, and we need to be more thoughtful about cannabinoid ratios when we’re treating conditions like chronic pain or anxiety in patients over 65.”
? Older adults’ reported preference for cannabidiol-dominant or balanced CBD-THC products over THC-only formulations may reflect legitimate concerns about psychoactive effects and cognitive side effects, though clinicians should recognize that preference data alone does not establish efficacy or safety superiority. The cannabinoid composition that feels subjectively more tolerable to patients does not necessarily correlate with therapeutic benefit for common geriatric conditions like chronic pain, sleep disturbance, or nausea, and individual responses remain highly variable. Important confounders include marketing influence, prior cannabis exposure, age-related pharmacokinetic changes that affect THC and CBD differently, and the substantial heterogeneity within product categories due to variable dosing and manufacturing standards. For practitioners considering cannabis recommendations in older patients, preference for lower-THC or CBD-enriched products may be a reasonable starting point to minimize acute cognitive or psychomotor risks, yet this choice should
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
